All the news Showing 10 of 61 articles from: Disease course and symptomsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Aspirin use associated with lower risk of liver cancer Liz Highleyman / 13 November 2018 Taking aspirin about twice a week for five years or more may reduce the risk of developing hepatocellular carcinoma (HCC) by about half, according to research presented this week at the AASLD Liver ... US FDA approves pembrolizumab immunotherapy for liver cancer Liz Highleyman / 12 November 2018 The US Food and Drug Administration last week granted accelerated approval for pembrolizumab (Keytruda), an immunotherapy drug known as a checkpoint inhibitor, for people with hepatocellular carcinoma (HCC). Over years or decades chronic hepatitis B ... What support do people with liver cirrhosis and their families need? Keith Alcorn / 09 October 2018 People with liver cirrhosis and their families need more information about their condition and prognosis and greater access to palliative care, a systematic review of studies on the needs of people with cirrhosis ... Fibroscan finds one in six people with hepatitis C in primary care have advanced liver disease Keith Alcorn / 28 August 2018 Measuring liver stiffness in primary care using Fibroscan is feasible and detects numerous cases of undiagnosed but advanced liver fibrosis, Australian researchers report in the journal BMJ Open this month. Despite availability of direct-acting ... Ramucirumab targeted therapy extends liver cancer survival Liz Highleyman / 09 July 2018 Ramucirumab (Cyramza), a type of targeted therapy that slows tumour growth by blocking blood vessel formation, led to improved overall survival and delayed disease progression in people with hepatocellular carcinoma ... T cell immunotherapy shows promise for treating liver cancer Liz Highleyman / 22 May 2018 Personalised immunotherapy reduces the risk of liver cancer recurrence and may lead to tumour regression, according to a pair of studies presented at the 2018 International Liver Congress last month in Paris. In ... Do fatigue and quality of life improve after hepatitis C is cured? Keith Alcorn / 15 May 2018 Patient-reported outcomes such as fatigue, vitality and mental health improve substantially in the two years following hepatitis C cure for people with cirrhosis, but people with cirrhosis are less likely ... Large Italian studies confirm no increase in liver cancer risk after hepatitis C treatment Keith Alcorn / 19 April 2018 Further research presented at this year’s International Liver Congress confirms that direct-acting antiviral (DAA) treatment leading to the cure of hepatitis C infection does not raise the risk of developing ... EASL updates liver cancer guidelines at International Liver Congress Liz Highleyman / 13 April 2018 The European Association for the Study of the Liver (EASL) presented updated clinical practice guidelines for the management of hepatocellular carcinoma (HCC) during a special session at the 2018 International Liver Congress yesterday ... Smoking threatens health gains from hepatitis C treatment, US researchers warn Keith Alcorn / 22 February 2018 People with hepatitis C in the United States are at least three times more likely to smoke than the general population but little is being done to help them stop ... ← Prev12345...7Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Transmission and prevention Diagnosis and monitoring Disease course and symptoms Treatment HIV and HBV HCV and HBV Hepatitis delta Living with HBV Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive